Resthetics

About Resthetics

Resthetics was founded in 2015 with the vision to convert waste anesthetic gas into a safe renewable resource. The company’s core technology, a porous crystalline organic framework, originated from interdisciplinary research conducted at the University of Houston. The porous crystalline organic framework not only has an extremely high affinity for fluorinated anesthetics, but also allows for desorption of the captured anesthetic molecules. They aim to sell the recaptured fluorinated anesthetics to manufacturers at a price that will be less than the cost of raw materials, time, and labor involved to produce new fluorinated anesthetic. Resthetics efficiently reduces HFC release by hospitals while generating a multimillion-dollar market. Their technology has received national acclaim in the Nature Communications scientific journal, has numerous peer-reviewed publications, and has been the focus of numerous grants from the National Science Foundation and The Welch Foundation. Resthetics has an exclusive licensing agreement in place with the University of Houston.